secwatch.observer — SEC 8-K summary
======================================

Issuer:     CV Sciences, Inc. (CVSI)
CIK:        0001510964
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0000950170-24-126787
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CV Sciences Q3 2024 revenue $3.9M, gross margin 46%, adjusted EBITDA loss of $75k
--------------------------------------------------------------------------------

- Revenue $3.9M, down 5% YoY from $4.1M; B2B sales fell 9% due to state CBD regulations.
- Gross margin improved to 46.0% from 45.1% YoY; operating loss narrowed to $0.3M from $0.4M.
- Adjusted EBITDA loss of $75k, near breakeven versus $0.4M loss a year ago.
- Cash balance $1.0M at quarter end; secured $0.9M net proceeds from Streeterville financing.
- Launched +PlusHLTH supplement line (CLARITY, PEACE, RESHAPE) and new pet chews.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1510964/000095017024126787/0000950170-24-126787-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1510964/000095017024126787/cvsi-20241114.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-126787

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer